Relation between atrial fibrillatory rate and markers of inflammation and haemostasis in persistent human atrial fibrillation

Arnljot Tveit; Andreas Bollmann; Ingebjørg Seljeflot; Daniela Husser; Martin Stridh; Leif Sörnmo; Harald Arnesen; Bertil S. Olsson; Pål Smith

doi:10.1160/TH08-07-0482

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(03): 601-603
DOI: 10.1160/TH08-07-0482

Letters to the Editor

Schattauer GmbH

Relation between atrial fibrillatory rate and markers of inflammation and haemostasis in persistent human atrial fibrillation

Arnljot Tveit

¹Department of Internal Medicine, Asker and Bærum Hospital, Rud, Norway

,

Andreas Bollmann

²Department of Cardiology, Lund University, Lund, Sweden

³Department of Electrophysiology, Heart Center Leipzig, Germany

,

Ingebjørg Seljeflot

⁴Center for Clinical Heart Research, Ulleval University Hospital, Oslo, Norway

,

Daniela Husser

²Department of Cardiology, Lund University, Lund, Sweden

³Department of Electrophysiology, Heart Center Leipzig, Germany

,

Martin Stridh

⁵Department of Electroscience, Lund University, Lund, Sweden

,

Leif Sörnmo

⁵Department of Electroscience, Lund University, Lund, Sweden

,

Harald Arnesen

⁴Center for Clinical Heart Research, Ulleval University Hospital, Oslo, Norway

,

Bertil S. Olsson

²Department of Cardiology, Lund University, Lund, Sweden

,

Pål Smith

¹Department of Internal Medicine, Asker and Bærum Hospital, Rud, Norway

› Author Affiliations

Abstract

Full Text

References

References
1 Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder?. Eur Heart J 2006; 27: 136-149.
2 Choudhury A, Lip GY. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol Haemost Thromb 2003; 33: 282-289.
3 Chung MK, Martin DO, Sprecher D. et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
4 Vene N, Mavri A, Kosmelj K. et al. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003; 90: 1163-1172.
5 Tveit A, Grundvold I, Olufsen M. et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007; 120: 85-91.
6 Stridh M, Sornmo L, Meurling CJ. et al. Characterization of atrial fibrillation using the surface ECG: time-dependent spectral properties. IEEE Trans Biomed Eng 2001; 48: 19-27.
7 Stridh M, Sornmo L. Spatiotemporal QRST cancellation techniques for analysis of atrial fibrillation. IEEE Trans Biomed Eng 2001; 48: 105-111.
8 Bollmann A, Husser D, Mainardi L. et al. Analysis of surface electrocardiograms in atrial fibrillation: techniques, research, and clinical applications. Europace 2006; 8: 911-926.
9 Bollmann A, Husser D, Stridh M. et al. Atrial fibrillatory rate and risk of left atrial thrombus in atrial fibrillation. Europace 2007; 9: 621-626.
10 Conway DS, Heeringa J, van der Kuip DA. et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke 2003; 34: 413-417.
11 Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.